X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

By Holly Campbell  |    March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...   Read More

Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy

By Tom Wilbur  |    March 22, 2019
At the end of 2018, the Centers for Medicare & Medicaid Services (CMS) introduced a dangerous proposed rule that would weaken the Medicare Part D six protected classes policy. The six protected...   Read More

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

By Katie Koziara  |    March 20, 2019
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing...   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

New report: Using march-in authority would jeopardize U.S. innovation

By Tom Wilbur  |    March 19, 2019
In 1980, Congress passed the Small Business Patent Procedures Act, better known as the Bayh-Dole Act, which created a uniform framework for transferring government-funded research into useful...   Read More

OptumRX: Sharing rebates with patients is “worth it”

By Holly Campbell  |    March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...   Read More

Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients

By Tom Wilbur  |    March 15, 2019
For over 10 years, one of the cornerstones of the Medicare Part D program has been to ensure the sickest and most vulnerable patients have access to the clinically critical medicines they rely on....   Read More

Special 301 submission calls for a level playing field for American innovators

By Megan Van Etten  |    March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...   Read More

New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors

By Nicole Longo  |    March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...   Read More

New “Prescription for Medicare” campaign focuses on impacts of wrong and right solutions for Medicare

By Juliet Johnson  |    March 6, 2019
Today, we are launching the “Prescription for Medicare” campaign which focuses on ensuring that changes made to Medicare are the right prescription for seniors. There’s a lot of talk in Washington...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates